Dr Weiguo Su has been an Executive Director since 2017 and Chief Executive Officer of the Company since March 4, 2022. He is also Chief Scientific Officer of the Company since 2012. He is also a member of Technical Committee of the Company. Dr Su has headed all drug discovery and research since he joined the Company, including master-minding the scientific strategy of the Company, being a key leader of the Oncology/Immunology operations, and responsible for the discovery of each and every small molecule drug candidate in our pipeline. Prior to joining the Company in 2005, Dr Su worked with the U.S. research and development department of Pfizer, Inc.
In 2017, Dr Su was granted the prestigious award by the China Pharmaceutical Innovation and Research Development Association (PhIRDA) as one of the Most Influential Drug R&D Leaders in China.
Dr Su received a Bachelor of Science degree in Chemistry from Fudan University in Shanghai and completed a PhD and Post-Doctoral Fellowship in Chemistry at Harvard University under the guidance of Nobel Laureate Professor E. J. Corey.
Mr Johnny Cheng has been an Executive Director since 2011 and Chief Financial Officer of the Company since 2008. He is a member of the Sustainability Committee of the Company.
Prior to joining the Company, Mr Cheng was Vice President, Finance of Bristol Myers Squibb in China and was a director of Sino-American Shanghai Squibb Pharmaceuticals Ltd. and Bristol-Myers Squibb (China) Investment Co. Ltd. in Shanghai between late 2006 and 2008.
Mr Cheng started his career as an auditor with Price Waterhouse (currently PricewaterhouseCoopers) in Australia and then KPMG in Beijing before spending eight years with Nestlé China where he was in charge of a number of finance and control functions in various operations. Mr Cheng received a Bachelor of Economics, Accounting Major from the University of Adelaide and is a member of Chartered Accountants Australia and New Zealand.
Dr Michael Shi is the Executive Vice President, Head of R&D and Chief Medical Officer of HUTCHMED. He oversees the drug discovery and development of the Company from strategy to execution.
Prior to joining the Company in 2022, Dr Shi was the Global Head of R&D and Chief Medical Officer at Transcenta Holding Limited where he helped build a strong global research and development organization across China and the U.S. and advanced seven programs into clinical development and multiple preclinical candidate nominations. Before that, Dr Shi worked at Novartis for over 15 years, where he held various senior leadership positions including global program clinical head in clinical development. He played key leadership roles in the clinical development of multiple novel oncology/hematology products from clinical proof-of-concept to successful execution of global pivotal trials, product registration and lifecycle management. Dr Shi is a member of the American Society of Clinical Oncology, European Society of Medical Oncology, American Society of Hematology, American Association for Cancer Research, Sino-American Pharmaceutical Association and an executive committee member of the
US-China Anticancer Association (USCACA). Dr Shi also worked as the program director of genetics variation at National Institutes of Health (“NIH”) under the direct supervision of former NIH director, Dr Francis Collins and was an adjunct assistant professor at the University of Michigan Medical School.
Dr Shi holds a PhD in Molecular Pharmacology and Toxicology from the University of Southern California, and conducted postdoctoral research at the Harvard Medical School. He received his medical education from Peking Union Medical College.
Dr Karen Atkin is the Executive Vice President and Chief Operating Officer of HUTCHMED. Prior to joining the Company in 2021, Dr Atkin spent 24 years at AstraZeneca in senior medical, regulatory, pharmacovigilance, R&D and commercial leadership roles, including as senior vice president of medical for biopharmaceuticals, vice president of the global infection, neuroscience and autoimmunity therapy area and the established brand business, country president of Indonesia and led China R&D for over four years. Dr Atkin is also a registered physician with advanced level qualifications in internal medicine and pharmaceutical medicine. Dr Atkin holds three Bachelor’s degrees in Physiology, Medicine and Surgery, respectively, from University College London. She graduated with a First Class Honors degree in Medicine, holds a Master of Business Administration from the Open University, is a member of the Royal College of Physicians and a fellow of the Faculty of Pharmaceutical Medicine in the UK.
Dr Zhenping Wu joined HUTCHMED in 2008 and is the Executive Vice President of Pharmaceutical Sciences and Manufacturing of the Company. Dr Wu has over 29 years of experience in drug discovery and development. His past positions include senior director of pharmaceutical sciences at Phenomix Corporation, a U.S.-based biotechnology company, director of pharmaceutical development at Pfizer Global Research & Development in California (formerly Agouron Pharmaceuticals) and a group leader at Roche at its Palo Alto site. He is a past chairman and president of the board of the Sino-American Biotechnology and Pharmaceutical Association. Dr Wu received a PhD from the University of Hong Kong and a Master in Business Administration from the University of California at Irvine.
Dr Zhou joined Shanghai Hutchison Pharmaceuticals in 2001.
Prior to this, Dr Zhou worked for Sanofi for over ten years rising from a Sales Representative to National Sales Director for China. Dr Zhou holds an MBA from China Europe International Business School (CEIBS) and a Master's degree in Medicine from Xian Medical University, China.
Mr Mark Lee is the Senior Vice President of Corporate Finance and Development of HUTCHMED. He began working in healthcare investment banking in the United States and Europe in 1998 and joined the Company in 2009. Based in the New York and London offices of Credit Suisse, Mr Lee was involved in the execution and origination of mergers, acquisitions, public and private financings and corporate strategy for life science companies such as AstraZeneca, Bristol-Myers Squibb and Genzyme, as well as others medical product and service companies. Mr Lee received his Bachelor’s degree in Biochemical Engineering with First Class Honors from University College London, where he was awarded a Dean’s Commendation. He also received a Master of Business Administration from the Massachusetts Institute of Technology’s Sloan School of Management.
Dr May Wang is the Senior Vice President of Business Development and Strategic Alliances of HUTCHMED. Prior to joining the Company in 2010, Dr Wang spent 16 years with Eli Lilly where she was the head of Eli Lilly’s Asian Biology Research and responsible for establishing and managing research collaborations in China and across Asia. Dr Wang holds numerous patents, has published more than 50 peer-reviewed articles and has given dozens of seminars and plenary lectures. Dr Wang received a PhD in Biochemistry from Purdue University.
Mr Hong Chen is the Senior Vice President and Chief Commercial Officer (China) of HUTCHMED. Prior to joining the Company in 2011, Mr Chen spent 12 years with Bristol-Myers Squibb and was last serving as its national sales & marketing director in China. Mr Chen received a Bachelor’s degree in Medicine from Nanjing Medical University and an EMBA from Cheung Kong Graduate School of Business.
Ms Cui leads the Government Affairs department of our Company in China. She has over 20 years of experience and management expertise in China’s pharmaceutical industry. She held senior management positions within the Sinopharm Group and the Shanghai Pharmaceutical Group from 2002, the two largest pharmaceutical groups in China.
Prior to joining HUTCHMED, she was the Vice President of Shanghai Shyndec Pharmaceutical Co., Ltd., which is the Chemical Pharmaceuticals platform of Sinopharm Group, where she was in charge of operations and strategy. Before that, she held various senior leadership positions including Board Chairman of Sino-American Shanghai Squibb Pharmaceuticals Co., Ltd. She was also the CEO of Shanghai Asia Pioneer Pharmaceutical Co., Ltd. and the Board Chairman of Shanghai New Asiatic Pharmaceutical Co., Ltd., both major companies of Shanghai Pharmaceutical Group.
In addition to her extensive experience in the pharmaceutical industry, Ms Cui is a current member of the Shanghai Committee of the Chinese People's Political Consultative Conference. She also served as a deputy to the Shanghai Municipal People's Congress for 10 years.
Ms Cui received a bachelor’s degree in Chemistry from Fudan University in 1987 and an EMBA from China Europe International Business School in 2003.
Ms Zhang joins HUTCHMED in March 2022. She has more than 20 years global & country HR management working experience in Pharmaceutical, Electronics and FMCG industries.
Prior to joining HUTCHMED, she was the Vice President of Hengrui Group, where she was in charge of global human resource management as CHRO. Before that, she worked in Novartis over 15 years, where she held various senior leadership positions including HR Head for REFS & Communications in Novartis NBS Switzerland, HR Head in Novartis TechOps U.S. San Carlos Site, HR Head for Sandoz China and HR Head for Novartis TechOps China Site.
Ms Zhang holds a Master degree in Economics from Beijing Capital University of Business & Economics in China, and holds a Master of Business Administration (MBA) from the IMD (International Institute for Management Development) in Switzerland.
Dr Fu oversees the quality and compliance of HUTCHMED’s clinical, laboratory, manufacturing, storage, and distribution operations globally.
He joined HUTCHMED with more than 22 years of quality management and leadership roles from the biopharmaceutical companies including Pfizer, AstraZeneca, Amgen, and Kura Oncology.
Dr Fu received his Ph.D. in Analytical Chemistry from the University of Maryland at College Park, USA in May, 1998.
Mr Charles Nixon has been Group General Counsel of HUTCHMED since May 2015 and has worked with the Company since 2006. Prior to joining the Company, Mr Nixon was group senior legal counsel for Hutchison Whampoa Limited (previously a listed company in Hong Kong and after a restructuring, a subsidiary of CK Hutchison Holdings Limited) in both Hong Kong and London and prior to that senior legal counsel for Three UK, the mobile phone operator. Mr Nixon has been with the CK Hutchison Group since 2001.
Mr Nixon received an LLB (Hons) from Middlesex University and is a qualified solicitor in England & Wales with over 30 years of experience.
Mr Leung joined the group in 2004 and took a leading role in establishing various joint ventures of the group, including Hutchison Baiyunshan and Hutchison Hain Organic. Since then, he was involved in numerous acquisition projects in the Chinese pharmaceuticals arena and oversaw the operations of GMP and GSP projects, and was involved with the setup of the Consumer Product Division business.
In 2014, he took up the position of Deputy General Manager of Hutchison Baiyunshan and spent most of his time in Guangzhou managing this OTC business, until its divestment in 2021. He continues to serve the group through different new initiatives, including group policy development and implementation, as well as running daily operation matters. Michael also has rich experience in intellectual property rights protection and corporate information systems.
Mr Leung holds a First Class Honours degree in Business Administration from Simon Fraser University, Canada, and received his MBA from the University of British Columbia, Canada.